Issue of Warrants and Change to Lease Agreement

28 Feb 2019

REDX PHARMA PLC

(“Redx” or “the Company”)

Alderley Park, 28 February 2019 Redx (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that, as previously noted in its 2018 Annual Report, it has successfully completed an agreement with Alderley Park Limited to significantly reduce its accommodation footprint in the Company’s Headquarters at Alderley Park, Cheshire.

As part of the agreement, on 27 February 2019, a Warrant to acquire 750,000 ordinary shares of 1p each in the share capital of the Company was issued to Alderley Park Limited as follows:

The subscription price payable per warrant share on exercise of the warrant is:

Price

No. of Shares

Date of Vesting

13.75p

125,000

27 February 2019

20p

125,000

27 February 2019

27p

125,000

27 February 2020

35p

125,000

27 February 2020

42.5p

125,000

27 February 2021

50p

125,000

27 February 2021

 

The Warrant will not become exercisable until the second anniversary of issue.

 

For further information, please contact:

 

Redx Pharma Plc T: +44 1625 469 920
Lisa Anson, Chief Executive Officer
 
Cantor Fitzgerald Europe (Nominated Advisor & Joint Broker) T: +44 20 7894 7000
Phil Davies
WG Partners LLP (Joint Broker) T: +44 20 3705 9330
Claes Spång/ Chris Lee/ David Wilson
FTI Consulting T: +44 20 3727 1000
Simon Conway/Stephanie Cuthbert

 

About Redx Pharma Plc 

Redx is a UK based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx’s vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.

 

If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/